THBD and Sepsis: Historically, proposed treatments for sepsis have focused on inhibiting inflammation (e.g., anti-TNFα or IL-1Ra therapy), promoting vascular integrity (via TIE2 stabilization), or counteracting the procoagulant shift of the endothelium (e.g., by using activated protein C, or recombinant soluble thrombomodulin) (199–205).